ArticleAmerican journal of translational research2025
Preoperative intravitreal injection of conbercept improves the efficacy of neovascular glaucoma surgery.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the therapeutic effects of intravitreal conbercept injection on neovascular glaucoma (NVG).
methodsSixty-seven patients with NVG were retrospectively selected and divided into a study group (n=34), which received intravitreal conbercept injection combined with trabeculectomy and panretinal photocoagulation; compared to a control group (n=33), which received trabeculectomy and panretinal photocoagulation only. The therapeutic effects, visual acuity, intraocular pressure, grade of iris neovascularization (NVI), pain score, complication rate, and anterior chamber angle were compared between the two groups.
resultsThe total effective rate in the study group was significantly higher than in the control group (97.06% vs. 81.82%, P<0.05). After 1 month of treatment, the study group showed significantly better visual acuity improvement and intraocular pressure control compared to the control group (both P<0.05). At 6 months of treatment, the proportion of patients with NVI grade 0-1 in the study group was significantly higher (94.11% vs. 48.48%, P<0.05). The proportion of patients with an anterior chamber angle ≥ grade 2 was also higher in the study group (70.59% vs. 39.39%, P<0.05). Additionally, the incidence of complications in the study group was lower (14.71% vs. 39.39%, P<0.05).
conclusionPreoperative intravitreal conbercept injection significantly improves NVI, visual acuity, and intraocular pressure control in patients with NVG, reduces the incidence of complications, and demonstrates both significant efficacy and good safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.